Surbpong Tanasanvimon

Appearances

COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
Date
May 19, 2024
BACKGROUND: Atezolizumab plus bevacizumab (ATEZO/BEV) and lenvatinib (LEN) have shown efficacy as first-line systemic treatments for unresectable hepatocellular carcinoma (HCC) in previous studies…
Presenter
Sangdao Boonkaya
Speakers
Kessarin Thanapirom
Nipaporn Siripon
Panarat Thaimai
Prooksa Ananchuensook
Supachaya Sriphoosanaphan
Surbpong Tanasanvimon
Sombat Treeprasertsuk
Piyawat Komolmit